Skip to content
Parakho

Senores Pharmaceuticals Ltd

NSE SENORESBSE 544319senorespharma.com

Q1 FY27, unaudited

Revenue
₹180.21 Cr
Profit after tax
₹30.45 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year ago6M FY26
Revenue from operations180.21+30.60%175.19
Other income2.81−16.37%17.67
Total income183.02+29.48%192.86
Employee benefit expense29.91+38.15%30.32
Finance costs7.17+42.26%8.46
Depreciation & amortisation9.94+65.67%9.30
Total expenses143.56+24.99%145.46
Profit before tax39.46+48.96%47.40
Tax expense9.01+69.68%10.73
Profit after tax30.45+43.77%36.67
Total comprehensive income30.96+43.00%78.59
Earnings per share
Earnings per share, basic₹6.61₹7.96
Earnings per share, diluted₹6.60₹7.96

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

6M FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Senores Pharmaceuticals reported consolidated revenue of Rs 180 crore for Q1 FY27, up 36% year-over-year, with EBITDA of Rs 54 crore growing 87% and PAT of Rs 31 crore growing 56%. Regulated market revenue grew 42% while emerging market revenue grew 30%, and management said the ANDA portfolio nearly doubled to 58 approved ANDAs as of June 2026 from 30 a year earlier. Management reiterated full-year FY27 guidance of 30% to 40% revenue growth and 50% to 60% PAT growth, and outlined a three-to-four-year revenue target of Rs 2,500 crore to Rs 3,000 crore.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 51 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 24 Aug 2026.